{"count": 12, "results": [{"_id": "32902818", "pmid": 32902818, "pmcid": "PMC7479299", "title": "A geroscience perspective on immune resilience and infectious diseases: a potential case for metformin", "journal": "Geroscience", "authors": ["Justice JN", "Gubbi S", "Kulkarni AS", "Bartley JM", "Kuchel GA", "Barzilai N"], "date": "2021-06-01T00:00:00Z", "doi": "10.1007/s11357-020-00261-6", "meta_date_publication": "2021 Jun", "meta_volume": "43", "meta_issue": "3", "meta_pages": "1093-1112", "score": 50266.06, "text_hl": "A geroscience perspective on immune resilience and @<m>DISEASE_Communicable_Diseases</m> @DISEASE_MESH:D003141 @@@infectious diseases@@@: a potential case for @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@", "citations": {"NLM": "Justice JN, Gubbi S, Kulkarni AS, Bartley JM, Kuchel GA, Barzilai N. A geroscience perspective on immune resilience and infectious diseases: a potential case for metformin Geroscience. 2021 Jun;43(3):1093-1112. PMID: 32902818", "BibTeX": "@article{32902818, title={A geroscience perspective on immune resilience and infectious diseases: a potential case for metformin}, author={Justice JN and Gubbi S and Kulkarni AS and Bartley JM and Kuchel GA and Barzilai N}, journal={Geroscience}, volume={43}, number={3}, pages={1093-1112}}"}}, {"_id": "34367059", "pmid": 34367059, "pmcid": "PMC8342037", "title": "Metformin and Covid-19: Focused Review of Mechanisms and Current Literature Suggesting Benefit", "journal": "Front Endocrinol (Lausanne)", "authors": ["Ibrahim S", "Lowe JR", "Bramante CT", "Shah S", "Klatt NR", "Sherwood N", "Aronne L", "Puskarich M", "Tamariz L", "Palacio A", "Bomberg E", "Usher M", "King S", "Benson B", "Vojta D", "Tignanelli C", "Ingraham N"], "date": "2021-07-22T00:00:00Z", "doi": "10.3389/fendo.2021.587801", "meta_date_publication": "2021", "meta_volume": "12", "meta_issue": "", "meta_pages": "587801", "score": 50257.395, "text_hl": "...@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ is the first-line medication for @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@type 2 diabetes@@@, but it also has a long history of improved outcomes in @<m>DISEASE_Communicable_Diseases</m> @DISEASE_MESH:D003141 @@@infectious diseases@@@, such as @DISEASE_Influenza_Human @DISEASE_MESH:D007251 @@@influenza@@@, @DISEASE_Hepatitis_C_Chronic @DISEASE_MESH:D019698 @@@hepatitis C@@@, and in-vitro assays of zika. ", "citations": {"NLM": "Ibrahim S, Lowe JR, Bramante CT, Shah S, Klatt NR, Sherwood N, Aronne L, Puskarich M, Tamariz L, Palacio A, Bomberg E, Usher M, King S, Benson B, Vojta D, Tignanelli C, Ingraham N. Metformin and Covid-19: Focused Review of Mechanisms and Current Literature Suggesting Benefit Front Endocrinol (Lausanne). 2021;12():587801. PMID: 34367059", "BibTeX": "@article{34367059, title={Metformin and Covid-19: Focused Review of Mechanisms and Current Literature Suggesting Benefit}, author={Ibrahim S and Lowe JR and Bramante CT and Shah S and Klatt NR and Sherwood N and Aronne L and Puskarich M and Tamariz L and Palacio A and Bomberg E and Usher M and King S and Benson B and Vojta D and Tignanelli C and Ingraham N}, journal={Front Endocrinol (Lausanne)}, volume={12}, pages={587801}}"}}, {"_id": "36474458", "pmid": 36474458, "title": "Metformin: new applications for an old drug.", "journal": "J Basic Clin Physiol Pharmacol", "authors": ["Naseri A", "Sanaie S", "Hamzehzadeh S", "Seyedi-Sahebari S", "Hosseini MS", "Gholipour-Khalili E", "Rezazadeh-Gavgani E", "Majidazar R", "Seraji P", "Daneshvar S", "Rezazadeh-Gavgani E"], "date": "2022-12-07T00:00:00Z", "doi": "10.1515/jbcpp-2022-0252", "meta_date_publication": "2022 Dec 7", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50252.453, "text_hl": "Regarding @<m>DISEASE_Communicable_Diseases</m> @DISEASE_MESH:D003141 @@@infectious diseases@@@, @DISEASE_Tuberculosis @DISEASE_MESH:D014376 @@@tuberculosis@@@ (@DISEASE_Tuberculosis @DISEASE_MESH:D014376 @@@TB@@@) and @DISEASE_Coronavirus_Infections @DISEASE_MESH:D018352 @@@coronavirus disease@@@ (@DISEASE_COVID_19 @DISEASE_MESH:D000086382 @@@COVID-19@@@) are among the conditions suggested to be affected by @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@. ", "citations": {"NLM": "Naseri A, Sanaie S, Hamzehzadeh S, Seyedi-Sahebari S, Hosseini MS, Gholipour-Khalili E, Rezazadeh-Gavgani E, Majidazar R, Seraji P, Daneshvar S, Rezazadeh-Gavgani E. Metformin: new applications for an old drug. J Basic Clin Physiol Pharmacol. 2022 Dec 7;():. PMID: 36474458", "BibTeX": "@article{36474458, title={Metformin: new applications for an old drug.}, author={Naseri A and Sanaie S and Hamzehzadeh S and Seyedi-Sahebari S and Hosseini MS and Gholipour-Khalili E and Rezazadeh-Gavgani E and Majidazar R and Seraji P and Daneshvar S and Rezazadeh-Gavgani E}, journal={J Basic Clin Physiol Pharmacol}}"}}, {"_id": "34007223", "pmid": 34007223, "pmcid": "PMC8123943", "title": "Metformin as a Potential Adjuvant Antimicrobial Agent Against Multidrug Resistant Bacteria", "journal": "Clin Pharmacol", "authors": ["Masadeh MM", "Alzoubi KH", "Masadeh MM", "Aburashed ZO"], "date": "2021-05-11T00:00:00Z", "doi": "10.2147/CPAA.S297903", "meta_date_publication": "2021", "meta_volume": "13", "meta_issue": "", "meta_pages": "83-90", "score": 50250.098, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ as a Potential Adjuvant Antimicrobial Agent Against Multidrug Resistant Bacteria", "citations": {"NLM": "Masadeh MM, Alzoubi KH, Masadeh MM, Aburashed ZO. Metformin as a Potential Adjuvant Antimicrobial Agent Against Multidrug Resistant Bacteria Clin Pharmacol. 2021;13():83-90. PMID: 34007223", "BibTeX": "@article{34007223, title={Metformin as a Potential Adjuvant Antimicrobial Agent Against Multidrug Resistant Bacteria}, author={Masadeh MM and Alzoubi KH and Masadeh MM and Aburashed ZO}, journal={Clin Pharmacol}, volume={13}, pages={83-90}}"}}, {"_id": "30474540", "pmid": 30474540, "title": "Repurposing of Existing Drugs for the Bacterial Infections: An In silico and In vitro Study.", "journal": "Infect Disord Drug Targets", "authors": ["Kapoor Y", "Sharma R", "Kumar A"], "date": "2020-01-01T00:00:00Z", "doi": "10.2174/1871526519666181126094244", "meta_date_publication": "2020", "meta_volume": "20", "meta_issue": "2", "meta_pages": "182-197", "score": 50247.047, "text_hl": "METHODS: Thus, in the current investigation, we have explored the existing drugs [@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ (Anti-@DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetic@@@), @CHEMICAL_Propranolol @CHEMICAL_MESH:D011433 @@@propranolol@@@ (Anti-@DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertensive@@@) and @CHEMICAL_Amitriptyline @CHEMICAL_MESH:D000639 @@@amitriptyline@@@ (antidepressant)] for treatment of @<m>DISEASE_Communicable_Diseases</m> @DISEASE_MESH:D003141 @@@infectious diseases@@@. ", "citations": {"NLM": "Kapoor Y, Sharma R, Kumar A. Repurposing of Existing Drugs for the Bacterial Infections: An In silico and In vitro Study. Infect Disord Drug Targets. 2020;20(2):182-197. PMID: 30474540", "BibTeX": "@article{30474540, title={Repurposing of Existing Drugs for the Bacterial Infections: An In silico and In vitro Study.}, author={Kapoor Y and Sharma R and Kumar A}, journal={Infect Disord Drug Targets}, volume={20}, number={2}, pages={182-197}}"}}, {"_id": "38296396", "pmid": 38296396, "title": "Metformin has immunomodulatory effects which support its potential use as adjunctive therapy in tuberculosis.", "journal": "Indian J Tuberc", "authors": ["Sutter A", "Landis D", "Nugent K"], "date": "2024-01-01T00:00:00Z", "doi": "10.1016/j.ijtb.2023.05.011", "meta_date_publication": "2024 Jan", "meta_volume": "71", "meta_issue": "1", "meta_pages": "89-95", "score": 50246.62, "text_hl": "...@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ is the preferred oral medication for @SPECIES_9606 @@@patients@@@ with @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@type 2 diabetes mellitus@@@, and this @CHEMICAL_Blood_Glucose @CHEMICAL_MESH:D001786 @@@blood glucose@@@-lowering and @GENE_INS @GENE_3630 @@@insulin@@@-sensitizing drug has immunomodulatory effects that could contribute to the management of @SPECIES_9606 @@@patients@@@ with various other @<m>DISEASE_Communicable_Diseases</m> @DISEASE_MESH:D003141 @@@autoimmune and infectious diseases@@@. ", "citations": {"NLM": "Sutter A, Landis D, Nugent K. Metformin has immunomodulatory effects which support its potential use as adjunctive therapy in tuberculosis. Indian J Tuberc. 2024 Jan;71(1):89-95. PMID: 38296396", "BibTeX": "@article{38296396, title={Metformin has immunomodulatory effects which support its potential use as adjunctive therapy in tuberculosis.}, author={Sutter A and Landis D and Nugent K}, journal={Indian J Tuberc}, volume={71}, number={1}, pages={89-95}}"}}, {"_id": "33609563", "pmid": 33609563, "title": "Metformin turns 62 in pharmacotherapy: Emergence of non-glycaemic effects and potential novel therapeutic applications.", "journal": "Eur J Pharmacol", "authors": ["Mbara KC", "Mofo Mato PE", "Driver C", "Nzuza S", "Mkhombo NT", "Gcwensa SK", "Mcobothi EN", "Owira PM"], "date": "2021-05-05T00:00:00Z", "doi": "10.1016/j.ejphar.2021.173934", "meta_date_publication": "2021 May 5", "meta_volume": "898", "meta_issue": "", "meta_pages": "173934", "score": 50246.56, "text_hl": "Anti-@DISEASE_Inflammation @DISEASE_MESH:D007249 @@@inflammatory@@@ and antioxidant effects of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ seem to qualify it as an adjunct therapy in treating @<m>DISEASE_Communicable_Diseases</m> @DISEASE_MESH:D003141 @@@infectious diseases@@@ such as @DISEASE_Tuberculosis @DISEASE_MESH:D014376 @@@tuberculosis@@@, @DISEASE_Virus_Diseases @DISEASE_MESH:D014777 @@@viral hepatitis@@@, and the current novel @DISEASE_COVID_19 @DISEASE_MESH:D000086382 @@@Covid-19 infections@@@. ", "citations": {"NLM": "Mbara KC, Mofo Mato PE, Driver C, Nzuza S, Mkhombo NT, Gcwensa SK, Mcobothi EN, Owira PM. Metformin turns 62 in pharmacotherapy: Emergence of non-glycaemic effects and potential novel therapeutic applications. Eur J Pharmacol. 2021 May 5;898():173934. PMID: 33609563", "BibTeX": "@article{33609563, title={Metformin turns 62 in pharmacotherapy: Emergence of non-glycaemic effects and potential novel therapeutic applications.}, author={Mbara KC and Mofo Mato PE and Driver C and Nzuza S and Mkhombo NT and Gcwensa SK and Mcobothi EN and Owira PM}, journal={Eur J Pharmacol}, volume={898}, pages={173934}}"}}, {"_id": "33081905", "pmid": 33081905, "title": "[Metformin: one of the possible options to reduce the mortality of severe coronavirus disease 2019?]", "journal": "Zhonghua Wei Zhong Bing Ji Jiu Yi Xue", "authors": ["Pan Y", "Han R", "He Y"], "date": "2020-09-01T00:00:00Z", "doi": "10.3760/cma.j.cn121430-20200514-00662", "meta_date_publication": "2020 Sep", "meta_volume": "32", "meta_issue": "9", "meta_pages": "1131-1134", "score": 50243.684, "text_hl": "Host-directed therapy (HDT) is an emerging therapeutic method in the field of anti-@DISEASE_Infections @DISEASE_MESH:D007239 @@@infection@@@, which can activate the self-protective immune response, suppress excessive @DISEASE_Inflammation @DISEASE_MESH:D007249 @@@inflammatory@@@ response, and be used to assist the treatment of traditional drugs to shorten the course of disease. @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ has been shown to be effective in HDT and can assist in the treatment of the @DISEASE_Virus_Diseases @DISEASE_MESH:D014777 @@@viral@@@ and @DISEASE_Bacterial_Infections @DISEASE_MESH:D001424 @@@bacterial@@@ @<m>DISEASE_Communicable_Diseases</m> @DISEASE_MESH:D003141 @@@infectious disease@@@. ", "citations": {"NLM": "Pan Y, Han R, He Y. [Metformin: one of the possible options to reduce the mortality of severe coronavirus disease 2019?] Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020 Sep;32(9):1131-1134. PMID: 33081905", "BibTeX": "@article{33081905, title={[Metformin: one of the possible options to reduce the mortality of severe coronavirus disease 2019?]}, author={Pan Y and Han R and He Y}, journal={Zhonghua Wei Zhong Bing Ji Jiu Yi Xue}, volume={32}, number={9}, pages={1131-1134}}"}}, {"_id": "37851178", "pmid": 37851178, "title": "Clinical impact of metformin exposure during Staphylococcus aureus bacteremia in patients with diabetes mellitus.", "journal": "Eur J Clin Microbiol Infect Dis", "authors": ["Lee JY", "Kim ES", "Chang E", "Bae S", "Jung J", "Kim MJ", "Chong YP", "Kim SH", "Choi SH", "Lee SO", "Kim YS"], "date": "2023-10-18T00:00:00Z", "doi": "10.1007/s10096-023-04679-6", "meta_date_publication": "2023 Oct 18", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50242.777, "text_hl": "PURPOSE: Increasing evidence has suggested that @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ may play positive roles in a wide range of @<m>DISEASE_Communicable_Diseases</m> @DISEASE_MESH:D003141 @@@infectious diseases@@@. ", "citations": {"NLM": "Lee JY, Kim ES, Chang E, Bae S, Jung J, Kim MJ, Chong YP, Kim SH, Choi SH, Lee SO, Kim YS. Clinical impact of metformin exposure during Staphylococcus aureus bacteremia in patients with diabetes mellitus. Eur J Clin Microbiol Infect Dis. 2023 Oct 18;():. PMID: 37851178", "BibTeX": "@article{37851178, title={Clinical impact of metformin exposure during Staphylococcus aureus bacteremia in patients with diabetes mellitus.}, author={Lee JY and Kim ES and Chang E and Bae S and Jung J and Kim MJ and Chong YP and Kim SH and Choi SH and Lee SO and Kim YS}, journal={Eur J Clin Microbiol Infect Dis}}"}}, {"_id": "37297798", "pmid": 37297798, "pmcid": "PMC10253158", "title": "Assessing Therapeutic Choices and Adherence to Antidiabetic Therapy in Naive Patients: A Retrospective Observational Study in a Local Health Authority of the Piedmont Region (Italy)", "journal": "Healthcare (Basel)", "authors": ["Armando LG", "Miglio G", "Baroetto Parisi R", "Esiliato M", "Rolando C", "Vinciguerra V", "Diarassouba A", "Cena C"], "date": "2023-06-05T00:00:00Z", "doi": "10.3390/healthcare11111655", "meta_date_publication": "2023 Jun 5", "meta_volume": "11", "meta_issue": "11", "meta_pages": "", "score": 50234.703, "text_hl": "Among 1927 @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@DM@@@-naive @SPECIES_9606 @@@patients@@@, 1361 started therapy with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@. Most of them received drugs related to @DISEASE_Cardiovascular_Diseases @DISEASE_MESH:D002318 @@@cardiovascular diseases@@@, @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertension@@@, and @<m>DISEASE_Communicable_Diseases</m> @DISEASE_MESH:D003141 @@@infectious diseases@@@ during the study period. ", "citations": {"NLM": "Armando LG, Miglio G, Baroetto Parisi R, Esiliato M, Rolando C, Vinciguerra V, Diarassouba A, Cena C. Assessing Therapeutic Choices and Adherence to Antidiabetic Therapy in Naive Patients: A Retrospective Observational Study in a Local Health Authority of the Piedmont Region (Italy) Healthcare (Basel). 2023 Jun 5;11(11):. PMID: 37297798", "BibTeX": "@article{37297798, title={Assessing Therapeutic Choices and Adherence to Antidiabetic Therapy in Naive Patients: A Retrospective Observational Study in a Local Health Authority of the Piedmont Region (Italy)}, author={Armando LG and Miglio G and Baroetto Parisi R and Esiliato M and Rolando C and Vinciguerra V and Diarassouba A and Cena C}, journal={Healthcare (Basel)}, volume={11}, number={11}}"}}]}